| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BNP; NPPB |
| Entrez GeneID | 4879 |
| clone | 3A6F7C7 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide corresponding to aa (Glu-Pro-Leu-Gln-Glu-Ser-Pro-Arg-Pro-Thr-Gly-Val-Trp-Cys) of human BNP, conjugated to KLH. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于BNP抗体的3篇示例参考文献(内容为示例，非真实文献)：
---
1. **文献名称**：*B-Type Natriuretic Peptide: A Critical Biomarker in Heart Failure Management*
**作者**：Maisel A.S., et al.
**摘要**：该综述探讨了BNP作为心力衰竭诊断和预后生物标志物的作用，重点分析了BNP抗体的检测原理及其在商业化检测试剂盒中的应用，比较了不同抗体对检测灵敏度和特异性的影响。
---
2. **文献名称**：*Development of a High-Sensitivity ELISA for BNP Detection Using Monoclonal Antibodies*
**作者**：Smith J.L., et al.
**摘要**：研究团队开发了一种基于单克隆抗体的ELISA检测方法，用于定量血清中的BNP。通过对抗体表位的筛选优化，显著提高了检测下限(达5 pg/mL)，并验证了其在心力衰竭患者中的临床适用性。
---
3. **文献名称**：*Comparison of BNP Antibody-Based Assays: Impact on Clinical Decision-Making*
**作者**：Apple F.S., et al.
**摘要**：该研究对比了不同厂商(如Roche、Abbott)的BNP检测平台，发现抗体选择差异(如针对BNP原分子或活性片段)可导致检测结果偏差，强调了标准化抗体校准对临床结果一致性的重要性。
---
4. **文献名称**：*BNP Antibody Cross-Reactivity with NT-proBNP: Implications for Diagnostic Accuracy*
**作者**：Daniels L.B., et al.
**摘要**：研究发现某些BNP抗体可能与NT-proBNP发生交叉反应，导致假阳性结果。通过表位定位实验，提出了优化抗体设计以减少干扰的策略，从而提高心力衰竭诊断的特异性。
---
注：以上文献信息为示例性内容，实际引用需以真实发表的论文为准。
**Background of BNP Antibodies**
B-type natriuretic peptide (BNP) is a cardiac hormone secreted primarily by ventricular cardiomyocytes in response to myocardial stretching or increased pressure. It plays a critical role in regulating blood pressure, fluid balance, and cardiovascular homeostasis. Elevated BNP levels are strongly associated with heart failure, making it a key biomarker for diagnosing and monitoring cardiac dysfunction.
BNP antibodies are specialized immunoglobulins designed to detect and quantify BNP in biological samples (e.g., blood). These antibodies are central to immunoassays, such as ELISA or chemiluminescent assays, used in clinical diagnostics. Most BNP assays employ a sandwich format, utilizing two monoclonal antibodies that bind distinct epitopes of the BNP molecule—one for capture and another for detection. This ensures high specificity and sensitivity, minimizing cross-reactivity with related peptides like NT-proBNP or ANP.
The development of BNP antibodies faces challenges due to BNP's short half-life, low circulating concentrations, and structural variability (e.g., degradation products). Advances in hybridoma technology and recombinant antibody engineering have improved affinity, stability, and reproducibility. Clinically, accurate BNP measurement aids in differentiating cardiac from non-cardiac causes of dyspnea, assessing heart failure severity, and guiding therapeutic decisions. Research also explores BNP antibodies in experimental models to study cardiac remodeling and biomarker kinetics.
In summary, BNP antibodies are indispensable tools in cardiovascular diagnostics, bridging biomarker science to patient care.
×
